Societal CDMO, Inc. Stock price

Equities

SCTL

US75629F1093

Pharmaceuticals

Delayed Nasdaq 04:00:00 2024-03-28 pm EDT 5-day change 1st Jan Change
1.08 USD -0.92% Intraday chart for Societal CDMO, Inc. +1.89% +208.13%
Sales 2024 * 94.93M Sales 2025 * 101M Capitalization 114M
Net income 2024 * -9M Net income 2025 * -6M EV / Sales 2024 * 1.2 x
Net cash position 2024 * - Net cash position 2025 * - EV / Sales 2025 * 1.13 x
P/E ratio 2024 *
-12.7 x
P/E ratio 2025 *
-18 x
Employees -
Yield 2024 *
-
Yield 2025 *
-
Free-Float 54.68%
More Fundamentals * Assessed data
Dynamic Chart
North American Morning Briefing : Stocks Edge -2- DJ
Societal CDMO, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
North American Morning Briefing : Markets on Hold -2- DJ
Stephens Downgrades Societal CDMO to Equalweight From Overweight, Raises Price Target to $1.10 From $1 MT
William Blair Downgrades Societal CDMO to Market Perform From Outperform MT
Wall Street Set to Open Higher Thursday as Inflation Data Meets Forecasts MT
Investors Await Slate of Economic Data as US Futures Move Lower in Thursday's Premarket Session MT
RBC Downgrades Societal CDMO to Sector Perform From Outperform, Trims Price Target to $1.10 From $1.25 Amid CoreRx Deal MT
CoreRx, Inc. entered into a definitive agreement to acquire Societal CDMO, Inc.. CI
Societal CDMO Signs Co-Marketing Deal With Benuvia Operations MT
Societal CDMO, Inc and Benuvia Sign Co-Marketing Agreement Designed to Promote Complementary CDMO and API Manufacturing Services to Drug Developers CI
Certain Warrants of Societal CDMO, Inc. are subject to a Lock-Up Agreement Ending on 23-NOV-2023. CI
Certain Restricted Stock Units of Societal CDMO, Inc. are subject to a Lock-Up Agreement Ending on 23-NOV-2023. CI
Certain Stock Options of Societal CDMO, Inc. are subject to a Lock-Up Agreement Ending on 23-NOV-2023. CI
Certain Common Stock of Societal CDMO, Inc. are subject to a Lock-Up Agreement Ending on 23-NOV-2023. CI
More news
1 day-0.92%
1 week+1.89%
Current month+0.93%
1 month+134.78%
3 months+208.57%
6 months+139.73%
Current year+208.13%
More quotes
1 week
1.08
Extreme 1.08
1.10
1 month
1.06
Extreme 1.06
1.10
Current year
0.31
Extreme 0.3078
1.10
1 year
0.26
Extreme 0.26
1.28
3 years
0.26
Extreme 0.26
3.29
5 years
0.26
Extreme 0.26
19.21
10 years
0.26
Extreme 0.26
19.21
More quotes
Managers TitleAgeSince
Chief Executive Officer 60 20-12-15
Director of Finance/CFO 46 17-06-05
Chief Operating Officer - 14-12-31
Members of the board TitleAgeSince
Director/Board Member 83 07-12-31
Chief Executive Officer 60 20-12-15
Chairman 68 07-12-31
More insiders
Date Price Change Volume
24-03-28 1.08 -0.92% 920,118
24-03-27 1.09 0.00% 382,535
24-03-26 1.09 +0.93% 286,304
24-03-25 1.08 -0.92% 94,371
24-03-22 1.09 +2.83% 1,123,859

Delayed Quote Nasdaq, March 28, 2024 at 04:00 pm EDT

More quotes
Societal CDMO, Inc. is a bi-coastal contract development and manufacturing organization (CDMO). The Company is engaged in spanning pre-investigational new drug development to commercial manufacturing and packaging for a range of therapeutic dosage forms with a primary focus on the area of small molecules. It is involved in CDMO providing therapeutic development, end-to-end regulatory support, clinical and commercial manufacturing, aseptic fill/finish, lyophilization, packaging and logistics services to the global pharmaceutical market. The Company's products include Ritalin LA, Focalin XR, Verelan PM, Verelan SR, Verapamil PM, Verapamil SR, Donnatal liquids and tablets and Scot-Tussin cough and cold liquids. Its manufacturing and development capabilities include product development from formulation through clinical trial and commercial manufacturing, and specialized capabilities for solid oral dosage forms and facilities to handle highly potent compounds and controlled substances.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
D+
More Ratings
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
4
Last Close Price
1.08 USD
Average target price
1.1 USD
Spread / Average Target
+1.85%
Consensus
  1. Stock
  2. Equities
  3. Stock Societal CDMO, Inc. - Nasdaq